SUBJECT: PIG BLOOD GENETICALLY ENGIN. FOR HUMAN USE FILE: UFO877 MUFONET-BBS NETWORK - MUTUAL UFO NETWORK ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ BIOTECHNOLOGY NEWS - WIRE ~~~~~~~~~~~~~~~~~~~~~~~~~~~ 旼컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴커 �=START= XMT: 08:40 Mon Jun 17 EXP: 09:00 Thu Jun 20 � � � 쿏NX CORP. GENETICALLY ENGINEERS PIG THAT PRODUCES HUMAN � 쿓EMOGLOBIN � � � 쿌NAHEIM, CA (JUNE 17) BUSINESS WIRE - DNX Corp., a � 쿛rinceton-based biotechnology firm, today announced that it � 쿴as developed genetically engineered, transgenic pigs that � 쿾roduce large quantities of recombinant human hemoglobin. � � � 쿥hen commercialized, DNX's blood substitute could provide a � 쿬ost-effective, virtually unlimited alternative to the human� 쿫lood supply that is entirely free from the threat of � 쿬ontamination by infectious agents that cause diseases such � 쿪s AIDS and hepatitis. In addition, DNX's recombinant � 쿴emoglobin-based transfusion product will be universally � 쿬ompatible with all blood types, eliminating the need for � 쿫lood typing and cross matching, and will have improved � 퀂helf-life and storage characteristics. � � � 쿏NX's announcement was made to the 1991 World Congress on � 쿎ell and Tissue Culture in Anaheim, Calif., by John Logan, � 퀆ice president of research at DNX. � � � 쿏NX anticipates submitting an investigational new drug (IND)� 쿪pplication during 1992. Pending approval by the U.S. Food � 쿪nd Drug Administration, human clinical trials could begin � 쿶n late 1992 or early 1993. � � � 쿞everal immediate applications of hemoglobin-based blood � 퀂ubstitute are apparent: (1) military stockpiling for use � 쿽n the battlefield where shelf-life, universal donor � 쿬apability, and no need for refrigeration are critical � 쿪dvantages; (2) in life-threatening trauma situations � 쿾articularly in geographically remote locations or during � 퀂easonal blood shortages; and (3) organ preservation during � 퀂torage and transport prior to transplantation. � � � 쿌ccording to market data compiled by the company, the market� 쿾otential of a safe, effective hemoglobin-based blood � 퀂ubstantial. In 1988, estimated 12 to 14 million units of � 쿫lood were transfused in the United States alone, at an � 쿪verage price to the patient of $175 per unit. The total � 퀇orldwide market is estimated to be $8 to $10 billion per � 퀉ear. � � � 쿥hile a price for DNX's product has yet to be determined, � 쿞chmitt noted that the company's goal is to develop a � 쿾roduct that will be economically viable when priced � 쿬omparably to the standard price of blood. � � � 쿑or several years, DNX has been collaborating with the Pig � 쿔mprovement Co. (PIC), Franklin, Ky., on the development of� 퀂uperior transgenic swine breeding stock. � � � 쿏NX Corp. is a privately held company that develops � 퀃ransgenic animals for the production and development of � 쿴uman biopharmaceuticals, including recombinant human � 쿴emoglobin and organs and tissues for xenogeneic � 퀃ransplantation. The company also develops Biodigms, � 퀃ransgenic laboratory animal model of human diseases and � 쿭isorders for use in drug efficacy and drug and chemical � 퀂afety testing. � � � 쿛harmacological and toxicological testing services employing� 쿏NX's Biodigms are offered on an exclusive basis through � 쿏NX's wholly owned subsidiary, DNX Pharmakon, Waverly, Penn.� � � 쿎ONTACT: DNX Corp., Princeton � � Paul Schmitt, 609/520-0300 � � or � � Hill and Knowlton, Waltham, Mass. � � Lorraine Ruff, 617/894-3100 (work) or � � 617/444-8294 (home) � � � �=END= � 읕컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴컴켸 ********************************************** * THE U.F.O. BBS - http://www.ufobbs.com/ufo * **********************************************